07:37 AM EDT, 09/02/2025 (MT Newswires) -- Olema Pharmaceuticals ( OLMA ) said Tuesday it has entered a clinical trial collaboration and supply agreement with Pfizer ( PFE ) for a combination metastatic breast cancer treatment.

The phase 1b/2 study will enroll about 35 patients in a clinical trial of palazastrant in combination with atirmociclib as a potential treatment for ER+/HER2- metastatic breast cancer, the company said.

Under the agreement, Pfizer ( PFE ) will provide Olema with atirmociclib for the planned trial, which is expected to begin in H2, Olema said.

The company said all clinical data and inventions from the trial will be jointly owned, with Olema retaining global commercial and marketing rights to palazestrant.

Olema shares were up more than 6% in recent Tuesday premarket activity.

Price: 5.79, Change: +0.33, Percent Change: +6.04